Exhibiting at VIV Asia 2025

Vaxxinova International BV, headquartered in Nijmegen, Netherlands, is a global specialist in veterinary vaccines and diagnostic solutions, with a primary focus on livestock and aquaculture health. As part of the EW Group, one of the world's largest animal genetics and health conglomerates, Vaxxinova is strategically positioned to deliver innovative, science-backed solutions that support animal welfare, sustainable production, and food security across the globe.

Core Business and Product Portfolio

Vaxxinova’s portfolio spans across licensed vaccines, autogenous (custom-made) vaccines, and advanced diagnostics. These offerings are tailored for the poultry, aqua, swine, cattle, and turkey segments.

• Licensed Vaccines:

  • Live and inactivated vaccines for poultry and aquaculture diseases
  • Branded under Vaxxon®, these include products like:
    • Vaxxon® MG: Mycoplasma gallisepticum vaccine for poultry
    • Vaxxon® FC: Inactivated combination vaccines for fowl cholera and colibacillosis

• Autogenous Vaccines:

  • Custom vaccines developed from field isolates
  • Applicable for pathogens with regional prevalence or emerging resistance
  • Used extensively in poultry (layers, broilers, breeders), aquaculture, and livestock (swine and bovine)

• Diagnostics & Services:

  • Centralized laboratories offering molecular diagnostics, serology, and bacteriology
  • Surveillance and strain typing to aid in vaccine formulation
  • Vaccine monitoring, epidemiology support, and farm-specific pathogen mapping

Vaxxinova’s vertically integrated capabilities—from diagnostics to vaccine production—make it a unique player in the customized preventive healthcare space.

Specialization and Core Strengths

Vaxxinova’s strength lies in precision veterinary immunology, especially its ability to offer tailor-made vaccines for regional or farm-specific pathogen profiles. Its differentiators include:

• Global R&D Network: Research centers in Brazil, Germany, Italy, Norway, Japan, USA, and the Netherlands
• Dual Regulatory Approvals: Products approved under both EU and local health authorities in multiple geographies
• Rapid Autogenous Vaccine Production: Capability to deliver vaccines within 4–6 weeks from isolate
• Integrated Diagnostics + Vaccines Model: Enables real-time disease surveillance and intervention

This end-to-end model enhances responsiveness to outbreaks and offers a competitive edge over standard vaccine manufacturers.

International Presence and Shipment Records

Vaxxinova has a strong international footprint with production, R&D, and diagnostic facilities in 13 countries. Its reach extends across Europe, Asia, the Americas, and the Middle East.

• Countries of Operation: Netherlands, Germany, Norway, Brazil, Italy, Chile, Egypt, USA, Japan, Jordan, and others
• Vaccine Registration: Approved in over 40 countries
• Top Export Markets: Latin America, Southeast Asia, MENA, and Europe
• Estimated Annual Vaccine Shipments: Over 15 million doses of autogenous and licensed vaccines combined

The company’s integration with the EW Group supply chain ensures efficient logistics and traceability across global markets.

Financial Performance

As a subsidiary of the privately held EW Group, detailed financials are not publicly disclosed. However, available indicators suggest:

• Estimated Group Revenue Impact: EW Group (parent company) exceeds EUR 3 billion in annual revenue
• Vaxxinova represents a significant component of EW Group’s animal health vertical, alongside genetics and nutrition
• Continuous investment in R&D and new diagnostics labs points to healthy financial backing and reinvestment strategy

Vaxxinova’s growth aligns with rising global demand for antimicrobial-free, preventive animal health solutions.

Certifications and Compliance

Vaxxinova adheres to the highest quality and regulatory standards globally:

• GMP Certified vaccine production units
• ISO 9001 and ISO 17025 certified diagnostic laboratories
• EU Marketing Authorizations for licensed vaccines
• Compliant with USDA, EMA, and local Ministry of Agriculture guidelines across markets

Autogenous vaccines are produced under strict biosecurity protocols with full batch traceability and client-specific documentation.

Target Market

Vaxxinova serves:

• Integrated poultry producers (layers, broilers, breeders)
• Aquaculture farms and integrators
• Swine and cattle farms, particularly those affected by region-specific disease challenges
• Veterinary service providers and distributors
• Public veterinary health programs and academic institutions

The company is especially relevant where regional strain variation or antimicrobial resistance limits the effectiveness of standard commercial vaccines.

Capabilities and Infrastructure

• Production Facilities: Located in the Netherlands, Brazil, Italy, Japan, and Egypt with capacity for both licensed and autogenous vaccines
• Diagnostics Labs: Central hubs in Germany, Netherlands, Brazil, and Norway with global sample shipping capabilities
• R&D Centers: Focused on immunology, antigen design, and pathogen surveillance
• Custom Manufacturing: End-to-end autogenous vaccine development—strain isolation, identification, production, packaging

Vaxxinova’s proprietary systems allow for real-time diagnostic data to inform vaccine design and delivery within weeks.

Customer Testimonials

Commercial poultry and aqua producers using Vaxxinova's autogenous vaccines report significant improvements in flock uniformity, mortality reduction, and lower antibiotic usage. Case studies published by the company highlight success stories in disease control across avian colibacillosis, salmonella, and vibrio spp. outbreaks.

Testimonials from integrators in Brazil and Southeast Asia emphasize fast turnaround and disease-specific targeting as key value drivers.

Achievements and Milestones

• Established in 2010, expanded rapidly through acquisitions and greenfield diagnostics labs
• Developed region-specific vaccine solutions for Asia and Latin America with proven efficacy
• Launched one of the first autogenous vaccine platforms for aquaculture in Norway
• Strategic collaborations with leading universities and research institutes in Europe and South America
• Recognized as a global leader in autogenous vaccines by industry bodies and veterinary organizations

Vaxxinova International BV continues to lead the evolution of veterinary immunology with its integrated, diagnostics-driven vaccine model that prioritizes precision, adaptability, and animal health security in a changing world.